Abstract
BackgroundIn China, both nirmatrelvir-ritonavir (Paxlovid) and azvudine have been granted approval to treat adult SARS-CoV-2-infected patients with moderate symptoms. Information about the clinical effect of the two available agents among...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have